Prognostic and predictive biomarkers in cancer

Current Cancer Drug Targets

Volumn 14, Issue 5, 2014, Pages 477-504

  Nair, Meera ^a   Sandhu, Sardul Singh ^b   Sharma, Anil K ^c  

^a PEOPLE S COLLEGE OF DENTAL SCIENCES AND RESEARCH CENTRE   (India)

^b RANI DURGAVATI UNIVERSITY   (India)

^c MAHARISHI MARKANDESHWAR DEEMED TO BE UNIVERSITY   (India)

Author keywords

Biomarkers; Cancer; Diagnostic markers; Genomics; Imaging; Metabolomics; Proteomics; Validation

Indexed keywords

5 METHYLCYTOSINE; BRCA1 PROTEIN; CLAUDIN 4; CYTOCHROME P450; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERYTHROPOIETIN; ESTROGEN RECEPTOR; FRAGILE HISTIDINE TRIAD PROTEIN; GAMMA SYNUCLEIN; HERMES ANTIGEN; INTESTINAL TREFOIL FACTOR; KI 67 ANTIGEN; MASPIN; MELANOMA ANTIGEN; MESOTHELIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; P CADHERIN; PROGESTERONE RECEPTOR; PROTEIN MLH1; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; SOMATOMEDIN B; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR MARKER; UNINDEXED DRUG; UROKINASE; UVOMORULIN; VON HIPPEL LINDAU PROTEIN;

BIOINFORMATICS; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SCREENING; CHROMATOGRAPHY; CHRONIC MYELOMONOCYTIC LEUKEMIA; COMPUTER ASSISTED DIAGNOSIS; COPY NUMBER VARIATION; DNA MICROARRAY; EARLY DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC VARIABILITY; GENOMICS; HUMAN; METABOLOMICS; MOLECULAR IMAGING; NEOPLASM; ONCOGENE; ONCOGENE NEU; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPECTROSCOPY; TOMOGRAPHY; TUMOR SUPPRESSOR GENE; BIOLOGY; DATABASE MANAGEMENT SYSTEM; METABOLISM; NEOPLASMS; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; COMPUTATIONAL BIOLOGY; DATABASE MANAGEMENT SYSTEMS; HUMANS; METABOLOMICS; NEOPLASMS; PROGNOSIS; PROTEOMICS;

EID: 84904735641     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140506111118     Document Type: Review

References (169)

1. World Cancer Research Fund International: Cancer Statistics. http://www. wcrf. org/cancer statistics/world cancer statistics. php (Accessed June 29, 2013)
2. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60(5), 277-300.
3. Brenner, D. E.; Hawk, E. Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions. Cancer Prev. Res. (Phila) 2013, 6(2), 71-73.
4. Vlahou, A. Network views for personalized medicine. Proteomics Clin. Appl. 2013, 7(5-6), 384-387.
5. Zhang, X.; Shi, L.; Chen, G.; Yap, Y. L. In: Omics Technologies in Cancer Biomarker Discovery; Xuewu Zhang, Ed., Landes Bioscience. 2011; pp. 129-137.
6. Lizardi, P. M.; Forloni, M.; Wajapeyee, N. Genome-wide approaches for ancer gene discovery. Trends Biotechnol. 2011, 29(11), 558-568.
7. Patterson, E. E.; Holloway, A. K.; Weng, J.; Fojo, T.; Kebebew, E. MicroRNA profling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011, 117(8), 1630-1639.
8. Asaga, S.; Kuo, C.; Nguyen, T.; Terpenning, M.; Giuliano, A. E.; Hoon, D. S. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 2011, 57(1), 84-91.
9. Biomarker Discovery Solution brochure-BGI Americas. Available from: http://bgiamericas. com/wp-content/uploads/2011/12/biomarkerdiscovery-solution-of-BGI. pdf.
10. Wang, W. W.; Spurdle, A. B.; Kolachana, P.; Bove, B.; Modan, B.; Ebbers, S. M.; Suthers, G.; Tucker, M. A.; Kaufman, D. J.; Doody, M. M.; Tarone, R. E.; Daly, M.; Levavi, H.; Pierce, H.; Chetrit, A.; Yechezkel, G. H.; Chenevix-Trench, G.; Offit, K.; Godwin, A. K.; Struewing, J. P. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of canceramong BRCA1/2 mutation carriers. Cancer Epidemiol. Biomarkers Prev. 2001, 10(9), 955-960.
11. Sidransky, D. Emerging molecular markers of cancer. Nat. Rev. Cancer 2002, 2(3), 210-219.
12. Guo, S.; Zou, J.; Wang, G. Advances in the proteomic discovery of novel therapeutic targets in cancer. Drug Des. Devel. Ther. 2013, 24(7), 1259-12571.
13. Spafford, M. F.; Koch, W. M.; Reed, A. L.; Califano, J. A.; Xu, L. H.; Eisenberger, C. F.; Yip, L.; Leong, P. L.; Wu, L.; Liu, S. X.; Jerónimo, C.; Westra, W. H.; Sidransky, D. Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. Clin. Cancer Res. 2001, 7, 607-612.
14. Mao, L.; Schoenberg, M. P.; Scicchitano, M.; Erozan, Y. S.; Merlo, A.; Schwab, D.; Sidransky, D. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996, 271(5249), 659-662.
15. Chen, X. Q. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat. Med. 1996, 2, 972-974.
16. Pakneshan, P.; Szyf, M.; Rabbani, S. A. Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications. Curr. Cancer Drug Targets 2005, 5, 471-488.
17. Albergaria, A.; Ribeiro, A. S.; Vieira, A. F.; Sousa, B.; Nobre, A. R.; Seruca, R.; Schmitt, F.; Paredes, J. P-cadherin role in normal breast development and cancer. Int. J. Dev. Biol. 2011, 55, 811-822.
18. Milicic, A.; Harrison, L. A.; Goodlad, R. A.; Hardy, R. G.; Nicholson, A. M.; Presz, M.; Sieber, O.; Santander, S.; Pringle, J. H.; Mandir, N.; East, P.; Obszynska, J.; Sanders, S.; Piazuelo, E.; Shaw, J.; Harrison, R.; Tomlinson, I. P.; McDonald, S. A.; Wright, N. A.; Jankowski, J. A. Ectopic expression of P-Cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. Cancer Res. 2008, 68, 7760-7768.
19. Lana, E.; Brun, M. E.; Rivals, I.; Selves, J.; Kirzin, S.; Lutsyk, A. P.; Gordiyuk, V. V.; Bibeau, F.; Rynditch, A.; De Sario, A. BAGE Hypomethylation is an early event in colon transformation and is frequent in histologically advanced adenomas. Cancers 2009, 1, 3-11.
20. Martin, V.; Ribieras, S.; Song-Wang, X. G.; Lasne, Y.; Frappart, L.; Rio, M. C.; Dante, R. Involvement of DNA methylation in the control of the expression of an estrogen-induced breast-cancerassociated protein (pS2) in human breast cancers. J. Cell Biochem. 1997, 65, 95-106.
21. Tanaka, T.; Nakamura, J.; Kitajima, Y.; Kai, K.; Miyake, S.; Hiraki, M.; Ide, T.; Koga, Y.; Noshiro, H. Loss of trefoil factor 1 is regulated by DNA methylation and is an independent predictive factor for poor survival in advanced gastric cancer. Int. J. Oncol. 2013, 42, 894-902.
22. Tokizane, T.; Shiina, H.; Igawa, M.; Enokida, H.; Urakami, S.; Kawakami, T.; Ogishima, T.; Okino, S. T.; Li, L. C.; Tanaka, Y.; Nonomura, N.; Okuyama, A.; Dahiya, R. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin. Cancer Res. 2005, 11, 5793-5801.
23. Karam, J. A.; Huang, S.; Fan, J.; Stanfield, J.; Schultz, R. A.; Pong, R-C.; Sun, X.; Mason, R. P.; Xie, X-J.; Niu, G.; Chen, X.; Frenkel, E. P.; Sagalowsky, A. I.; Hsieh, J-T. Upregulation of TRAG3 gene in urothelial carcinoma of the bladder. Int. J. Cancer 2011, 128, 2823-2832.
24. Cui, H.; Onyango, P.; Brandenburg, S.; Wu, Y.; Hsieh, C. L.; Feinberg, A. P. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 2002, 62, 6442-6446.
25. Barciszewska, A-M.; Murawa, D.; Gawronska, I.; Murawa, P.; Nowak, S.; Barciszewska, M. Z. Analysis of 5-Methylcytosine in DNA of Breast and Colon Cancer Tissues. IUBMB Life 2007, 59, 765-770.
26. Cho, M.; Uemura, H.; Kim, S. C.; Kawada, Y.; Yoshida, K.; Hirao, Y.; Konishi, N.; Saga, S.; Yoshikawa, K. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. Br. J. Cancer 2001, 85, 563-567.
27. Yoshida, M.; Nosaka, K.; Yasunaga, J.; Nishikata, I.; Morishita, K.; Matsuoka, M. Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. Blood 2004, 103, 2753-27560.
28. Waldner, M. J.; Wirtz, S.; Becker, C.; Seidel, D.; Tubbe, I.; Cappel, K.; Hähnel, P. S.; Galle, P. R.; Schuler, M.; Neurath, M. F. Perforin deficiency attenuates inflammation and tumor growth in colitisassociated cancer. Inflamm. Bowel Dis. 2010, 16, 559-567.
29. Gupta, A.; Godwin, A. K.; Vanderveer, L.; Lu, A.; Liu, J. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res. 2003, 63, 664-673.
30. Laner, T.; Schulz, W. A.; Engers, R.; Müller, M.; Florl, A. R. Hypomethylation of the XIST gene promoter in prostate cancer. Oncol. Res. 2005, 15, 257-264.
31. Volgger, B.; Kurz, K.; Zöschg, K.; Theurl, I.; Ciresa-König, A.; Marth, C.; Weiss, G. Importance of erythropoietin receptor expression in tumour tissue for the clinical course of breast cancer. Anticancer Res. 2010, 30, 3721-3726.
32. Liu, T.; Yang, M.; Yang, S.; Ge, T.; Gu, L.; Lou, G. Metastasisassociated protein 1 is a novel marker predicting survival and lymph nodes metastasis in cervical cancer. Hum. Pathol. 2013, 44, 2275-2281.
33. Hoffmann, M. J.; Schulz, W. A. Causes and consequences of DNA hypomethylation in human cancer. Biochem. Cell Biol. 2005, 83, 296-321.
34. Qu, G. Z.; Grundy, P. E.; Narayan, A.; Ehrlich, M. Frequent hypomethylation in Wilms tumorsof pericentromeric DNA in chromosomes 1 and 16. Cancer Genet. Cytogenet. 1999, 109, 34-39.
35. Widschwendter, M.; Jiang, G.; Woods, C.; Müller, H. M.; Fiegl, H.; Goebel, G.; Marth, C.; Müller-Holzner, E.; Zeimet, A. G.; Laird, P. W.; Ehrlich, M. DNA hypomethylation and ovarian cancer biology. Cancer Res. 2004, 64, 4472-4480.
36. Goelz, S. E.; Vogelstein, B.; Hamilton, S. R.; Feinberg, A. P. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985, 228, 187-190.
37. Takaha, N.; Resar, L. M.; Vindivich, D.; Coffey, D. S. High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate 2004, 60, 160-167.
38. Khalkhali-Ellis, Z. Maspin: the new frontier. Clin Cancer Res 2006, 12, 7279-7283.
39. Cho, B.; Lee, H.; Jeong, S.; Bang, Y. J.; Lee, H. J.; Hwang, K. S.; Kim, H. Y.; Lee, Y. S.; Kang, G. H.; Jeoung, D. I. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem. Biophys. Res. Commun. 2003, 307, 52-63.
40. Lee, T. S.; Kim, J. W.; Kang, G. H.; Park, N. H.; Song, Y. S.; Kang, S. B.; Lee, H. P. DNA hypomethylation ofCAGE promotors in squamous cell carcinoma of uterine cervix. Ann. N. Y. Acad. Sci. 2006, 1091, 218-224.
41. Nakanishi, H.; Suda, T.; Katoh, M.; Watanabe, A.; Igishi, T.; Kodani, M.; Matsumoto, S.; Nakamoto, M.; Shigeoka, Y.; Okabe, T.; Oshimura, M.; Shimizu, E. Loss of imprinting of PEG1/MEST in lung cancer cell lines. Oncol. Rep. 2004, 12, 1273-1278.
42. Yu, Y.; Xu, F.; Peng, H.; Fang, X.; Zhao, S.; Li, Y.; Cuevas, B.; Kuo, W. L.; Gray, J. W.; Siciliano, M.; Mills, G. B.; Bast, R. C. Jr. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 214-219.
43. Chinnam, M.; Goodrich, D. W. RB1, development, and cancer. Curr. Top. Dev. Biol. 2011, 94, 129-169.
44. Chan, K. Y.; Ozçelik, H.; Cheung, A. N.; Ngan, H. Y.; Khoo, U. S. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res. 2002, 62, 4151-4156.
45. Woodson, K.; Mason, J.; Choi, S. W.; Hartman, T.; Tangrea, J.; Virtamo, J.; Taylor, P. R.; Albanes, D. Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. Cancer Epidemiol. Biomarkers Prev. 2001, 10, 69-74.
46. Kim, K. H.; Choi, J. S.; Kim, I. J.; Ku, J. L.; Park, J. G. Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues. World J. Gastroenterol. 2006, 12, 5651-5657.
47. Woloszynska-Read, A.; James, S. R.; Song, C.; Jin, B.; Odunsi, K.; Karpf, A. R. BORIS/CTCFL expression is insufficient for cancergermline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer Immun. 2010, 10, 6.
48. Sato, N.; Matsubayashi, H.; Abe, T.; Fukushima, N.; Goggins, M. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin. Cancer Res. 2005, 11, 4681-4688.
49. Wang, Y.; Wang, L.; Li, D.; Wang, H. B.; Chen, Q. F. Mesothelin promotes invasion and metastasis in breast cancer cells. J. Int. Med. Res. 2012, 40, 2109-2116.
50. Vestergaard, E. M.; Nexø, E.; Tørring, N.; Borre, M.; Ørntoft, T. F.; Sørensen, K. D. Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. Int. J. Cancer 2010, 127, 1857-1865.
51. Sato, N.; Fukushima, N.; Matsubayashi, H.; Goggins, M. Identification of maspin and S100P as novel targets in cancer using global gene expression profiling. Oncogene 2004, 23, 1531-1538.
52. Gupte S, Gupte S-B. Recent Advances in Pediatrics-20: Hot Topics. Jaypee Brothers Medical Publishers: New Delhi, 2011.
53. Baba, Y.; Watanabe, M.; Murata, A.; Shigaki, H.; Miyake, K.; Ishimoto, T.; Iwatsuki, M.; Iwagami, S.; Yoshida, N.; Oki, E.; Sakamaki, K.; Nakao, M.; Baba, H. LINE-1 hypomethylation, DNA copy number alterations, and CDK6 amplification in esophageal squamous cell carcinoma. Clin. Cancer Res. 2014, 20(5), 1114-1124
54. Iacobuzio-Donahue, C. A.; Maitra, A.; Olsen, M.; Lowe, A. W.; van Heek, N. T.; Rosty, C.; Walter, K.; Sato, N.; Parker, A.; Ashfaq, R.; Jaffee, E.; Ryu, B.; Jones, J.; Eshleman, J. R.; Yeo, C. J.; Cameron, J. L.; Kern, S. E.; Hruban, R. H.; Brown, P. O.; Goggins, M. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am. J. Pathol. 2003, 162, 1151-1162.
55. Traverso, G.; Shuber, A.; Levin, B.; Johnson, C.; Olsson, L.; Schoetz, D. J. Jr.; Hamilton, S. R.; Boynton, K.; Kinzler, K. W.; Vogelstein, B. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N. Engl. J. Med. 2002, 346(5), 311-320.
56. Usadel, H.; Brabender, J.; Danenberg, K. D.; Jerónimo, C.; Harden, S.; Engles, J.; Danenberg, P. V.; Yang, S.; Sidransky, D. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 2002, 62(2), 371-375.
57. Lee, E.; McKean-Cowdin, R.; Ma, H.; Spicer, D. V.; Van Den Berg, D.; Bernstein, L.; Ursin, G. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation, results from a population-based study of young women. J. Clin. Oncol. 2011, 29(33), 4373-4380.
58. Graff, J. R.; Herman, J. G.; Lapidus, R. G.; Chopra, H.; Xu, R.; Jarrard, D. F.; Isaacs, W. B.; Pitha, P. M.; Davidson, N. E.; Baylin, S. B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995, 55, 5195-5199.
59. Xiao, W.; Graham, P. H.; Power, C. A.; Hao, J.; Kearsley, J. H.; Li, Y. CD44 is a biomarker associated with human prostate cancer radiation sensitivity. Clin. Exp. Metastasis 2012, 29 (1), 1-9.
60. Chang, M. H.; Lee, K.; Lee, K. Y.; Kim, Y. S.; Kim, Y. K.; Kang, J. H. Prognostic role of integrin β1.; E-cadherin.; and rac1 expression in small cell lung cancer. APMIS 2012, 120(1), 28-38.
61. Broussard, E. K.; Kim, R.; Wiley, J. C.; Marquez, J. P.; Annis, J. E.; Pritchard, D.; Disis, M. L. Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions. Cancer Prev. Res. (Phila) 2013, 7, 666-674.
62. Esteller, M.; Sanchez-Cespedes, M.; Rosell, R.; Sidransky, D.; Baylin, S. B.; Herman, J. G. Detection of aberrant promoter hyper-methylation of tumor suppressor genes in serum DNA from nonsmall cell lung cancer patients. Cancer Res. 1999, 59(1), 67-70.
63. Sanchez-Cespedes, M.; Esteller, M.; Wu, L.; Nawroz-Danish, H.; Yoo, G. H.; Koch, W. M.; Jen, J.; Herman, J. G.; Sidransky, D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000, 60(4), 892-895.
64. Lo, K. W.; Tsang, Y. S.; Kwong, J.; To, K. F.; Teo, P. M.; Huang, D. P. Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. Int. J. Cancer 2002, 98(5), 651-655.
65. Jerónimo, C.; Henrique, R.; Campos, P. F.; Oliveira, J.; Caballero, O. L.; Lopes, C.; Sidransky, D. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J. Clin. Pathol. 2003, 56(1), 52-55.
66. Vesuna, F.; Lisok, A.; Kimble, B.; Domek, J.; Kato, Y.; van der Groep, P.; Artemov, D.; Kowalski, J.; Carraway, H.; van Diest, P.; Raman, V. Twist contributes to hormone resistance in breast cancer by down regulating estrogen receptor-α. Oncogene 2012, 31(27), 3223-3234.
67. Silveira, A. P.; Da Silva, Manoel-Caetano, F.; Aoki, S.; Yamasaki, L. H.; Rahal, P.; Silva, A. E. Gene mutations and polymorphisms of TP53 and FHIT in chronic esophagitis and esophageal carcinoma. Anticancer Res. 2011, 31(5), 1685-1690.
68. Jerónimo, C.; Usadel, H.; Henrique, R.; Oliveira, J.; Lopes, C.; Nelson, W. G.; Sidransky, D. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl. Cancer Inst. 2001, 93(22), 1747-1752.
69. Hagen, C. E.; Lefferts, J.; Hornick, J. L.; Srivastava, A. "Nul pattern" of immunoreactivity in a Lynch syndrome-associated colon cancer due to germline MSH2 mutation and somatic MLH1 hypermethylation. Am. J. Surg. Pathol. 2011, 35(12), 1902-1905.
70. Eissa, S.; Swellam, M.; El-Khouly, I. M.; Kassim, S. K.; Shehata, H.; Mansour, A.; Esmat, M.; Nossier, A. I.; Hamdy, M. A.; Awad, N. M.; El-Ahmady, O. Aberrant methylation of RARbeta2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer. Cancer Epidemiol. Biomarkers Prev. 2011, 20(8), 1657-1664.
71. Buhmeida, A.; Merdad, A.; Al-Maghrabi, J.; Al-Thobaiti, F.; Ata, M.; Bugis, A.; Syrjänen, K.; Abuzenadah, A.; Chaudhary, A.; Gari, M.; Al-Qahtani, M.; Dallol, A. RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. Anticancer Res. 2011, 31(9), 2975-2981.
72. Watanabe, T.; Kobunai, T.; Yamamoto, Y.; Matsuda, K.; Ishihara, S.; Nozawa, K.; Iinuma, H.; Ikeuchi, H. Gene expression of vascular endothelial growth factor A, thymidylate synthase and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. Dis. Colon Rectum 2011, 54(8), 1026-1035.
73. Das, P. M.; Singal, R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22, 4632-4642.
74. Gama-Sosa, M. A.; Slagel, V. A.; Trewyn, R. W.; Oxenhandler, R.; Kuo, K. C.; Gehrke, C. W.; Ehrlich, M. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 1983, 11(19), 6883-6894.
75. Stephenson, J.; Akdag, R.; Ozbek, N.; Mufti, G. J. Methylation status within exon 3 of the c-myc gene as a prognostic marker in myeloma and leukaemia. Leuk. Res. 1993, 17(3), 291-293.
76. Sharrard, R. M.; Royds, J. A.; Rogers, S.; Shorthouse, A. J. Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br. J. Cancer 1992, 65(5), 667-672.
77. Yang, W.; Soares, J.; Greninger, P.; Edelman, E. J.; Lightfoot, H.; Forbes, S.; Bindal, N.; Beare, D.; Smith, J. A.; Thompson, I. R.; Ramaswamy, S.; Futreal, P. A.; Haber, D. A.; Stratton, M. R.; Benes, C.; McDermott, U.; Garnett, M. J. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013, 41, D955-D961.
78. Palmnas, M. S. A.; Vogel, H. J. The future of NMR metabolomics in cancer therapy: Towards personalizing treatment and developing targeted drugs? Metabolites 2013, 3(2), 373-396.
79. Denkert, C.; Bucher, E.; Hilvo, M.; Salek, R.; Orešič, M.; Griffin, J.; Brockmöller, S.; Klauschen, F.; Loibl, S.; Barupal, D. K.; Budczies, J.; Iljin, K.; Nekljudova, V.; Fiehn, O. Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med. 2012, 4(4), 37.
80. Li, M.; Song, Y.; Cho, N.; Chang, J. M.; Koo, H. R.; Yi, A.; Kim, H.; Park, S.; Moon, W. K. An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. PLoS One 2011, 6(10), e25563.
81. Jiménez, B.; Mirnezami, R.; Kinross, J.; Cloarec, O.; Keun, H. C.; Holmes, E.; Goldin, R. D.; Ziprin, P.; Darzi, A.; Nicholson, J. K. 1H HR-MAS NMR spectroscopy of tumor-induced local metabolic "field-effects" enables colorectal cancer staging and prognostication. J. Proteome Res. 2013, 12(2), 959-968.
82. Wang, L.; Chen, J.; Chen, L.; Deng, P.; Bu, Q.; Xiang, P.; Li, M.; Lu, W.; Xu, Y.; Lin, H.; Wu, T.; Wang, H.; Hu, J.; Shao, X.; Cen, X.; Zhao, Y. L. 1H-NMR based metabonomic profiling of human esophageal cancer tissue. Mol. Cancer 2013, 12, 25.
83. Zhang, X.; Xu, L.; Shen, J.; Cao, B.; Cheng, T.; Zhao, T.; Liu, X.; Zhang, H. Metabolic signatures of esophageal cancer: NMRbased metabolomics and UHPLC-based focused metabolomics of blood serum. Biochim. Biophys. Acta 2013, 1832(8), 1207-12016.
84. Farshidfar, F.; Weljie, A. M.; Kopciuk, K.; Buie, W. D.; Maclean, A.; Dixon, E.; Sutherland, F. R.; Molckovsky, A.; Vogel, H. J.; Bathe, O. F. Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med. 2012, 4(5), 42.
85. Kobayashi, T.; Nishiumi, S.; Ikeda, A.; Yoshie, T.; Sakai, A.; Matsubara, A.; Izumi, Y.; Tsumura, H.; Tsuda, M.; Nishisaki, H.; Hayashi, N.; Kawano, S.; Fujiwara, Y.; Minami, H.; Takenawa, T.; Azuma, T.; Yoshida, M. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 2013, 22(4), 571-579.
86. Budczies, J.; Denkert, C.; Müller, B. M.; Brockmöller, S. F.; Klauschen, F.; Györffy, B.; Dietel, M.; Richter-Ehrenstein, C.; Marten, U.; Salek, R. M.; Griffin, J. L.; Hilvo, M.; Orešič, M.; Wohlgemuth, G.; Fiehn, O. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue-a GC-TOFMS based metabolomics study. BMC Genomics 2012, 13, 334.
87. Yang, C.; Richardson, A. D.; Osterman, A.; Smith, J. W. Profiling of central metabolism in human cancer cells by two-dimensional NMR, GC-MS analysis, and isotopomer modeling. Metabolomics 2008, 4(1), 13-29.
88. Beger, R. D.; Sun, J.; Schnackenberg, L. K. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 2010, 243(2), 154-166.
89. Want, E.; Masson, P. Processing and analysis of GC/LC-MSbased metabolomics data. Methods Mol. Biol. 2011, 708, 277-298.
90. Fukui, Y.; Itoh, K. A Plasma metabolomic investigation of colorectal cancer patients by liquid chromatography-mass spectrometry. The Open Analytical Chemistry Journal 2010, 4, 1-9.
91. Zeng, X.; Hood, B. L.; Zhao, T.; Conrads, T. P.; Sun, M.; Gopalakrishnan, V.; Grover, H.; Day, R. S.; Weissfeld, J. L.; Wilson, D. O.; Siegfried, J. M.; Bigbee, W. L. Lung cancer serum biomarker discovery using label free LCMS/MS. J. Thorac. Oncol. 2011, 6(4), 725-734.
92. Issaq, H. J.; Nativ, O.; Waybright, T.; Luke, B.; Veenstra, T. D.; Issaq, E. J.; Kravstov, A.; Mullerad, M. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J. Urol. 2008, 179(6), 2422-6.
93. Loftus, N. J.; Lai, L.; Wilkinson, R. W.; Odedra, R.; Wilson, I. D.; Barnes, A. J. Global metabolite profiling of human colorectal cancer xenografts in mice using HPLC-MS/MS. J. Proteome Res. 2013, 12(6), 2980-2986.
94. Fan, L.; Zhang, W.; Yin, M.; Zhang, T.; Wu, X.; Zhang, H.; Sun, M.; Li, Z.; Hou, Y.; Zhou X.; Lou, G.; Li, K. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform. Acta Oncol. 2012, 51(4), 473-479.
95. Liu, R.; Peng, Y.; Li, X.; Wang, Y.; Pan, E.; Guo, W.; Pu, Y.; Yin, L. Identification of plasma metabolomic profiling for diagnosis of esophageal squamous-cell carcinoma using an UPLC/TOF/MS platform. Int. J. Mol. Sci. 2013, 14(5), 8899-8911.
96. Bi, H.; Krausz, K. W.; Manna, S. K.; Li, F.; Johnson, C. H.; Gonzalez, F. J. Optimization of harvesting, extraction, and analytical protocols for UPLC-ESI-MS-based metabolomic analysis of adherent mammalian cancer cells. Anal. Bioanal. Chem. 2013, 405(15), 5279-5289.
97. Jain, M.; Nilsson, R.; Sharma, S.; Madhusudhan, N.; Kitami, T.; Souza, A. L.; Kafri, R.; Kirschner, M. W.; Clish, C. B.; Mootha, V. K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012, 336(6084), 1040-1044.
98. Hori, S.; Nishiumi, S.; Kobayashi, K.; Shinohara, M.; Hatakeyama, Y.; Kotani, Y.; Hatano, N.; Maniwa, Y.; Nishio, W.; Bamba, T.; Fukusaki, E.; Azuma, T.; Takenawa, T.; Nishimura, Y.; Yoshida, M. A metabolomic approach to lung cancer. Lung Cancer 2011, 74(2), 284-292.
99. Nieva, C.; Marro, M.; Santana-Codina, N.; Rao, S.; Petrov, D.; Sierra, A. The lipid phenotype of breast cancer cells characterized by Raman microspectroscopy: towards a stratification of malignancy. PLoS One 2012, 7(10), e46456.
100. Benjamin, D. I.; Cravatt, B. F.; Nomura, D. K. Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab. 2012, 16(5), 565-577.
101. Aboud, O. A.; Weiss, R. H. New opportunities from the cancer metabolome. Clin. Chem. 2013, 59(1), 138-146.
102. Stingele, S.; Stoehr, G.; Peplowska, K.; Cox, J.; Mann, M.; Storchova, Z. Global analysis of genome, transcriptome and proteome reveals the response to aneuploidy in human cells. Mol. Syst. Biol. 2012, 8, 608.
103. Kondo, Y.; Nishiumi, S.; Shinohara, M.; Hatano, N.; Ikeda, A.; Yoshie, T.; Kobayashi, T.; Shiomi, Y.; Irino, Y.; Takenawa, T.; Azuma, T.; Yoshida, M. Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry. Biomark. Med. 2011, 5, 451-460.
104. Song, G.; Qin, T.; Liu, H.; Xu, G. B.; Pan, Y. Y.; Xiong, F. X.; Gu, K. S.; Sun, G. P.; Chen, Z. D. Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer 2010, 67(2), 227-231.
105. Yang Ai, S. S.; Hsu, K.; Herbert, C.; Cheng, Z.; Hunt, J.; Lewis, C. R.; Thomas, P. S. Mitochondrial DNA mutations in exhaled breath condensate of patients with lung cancer. Respir. Med. 2013, 107(6), 911-918.
106. Kouremenos, K. A.; Johansson, M.; Marriott, P. J. Advances in gas chromatographic methods for the identification of biomarkers in cancer. J. Cancer 2012, 3, 404-420.
107. Nicholson, J. K.; Wilson, I. D. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2003, 2(8), 668-676.
108. Griffin, J. L.; Shockcor, J. P. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004, 4(7), 551-561.
109. Beger, R. D. A review of applications of metabolomics in cancer. Metabolites 2013, 3(3), 552-574.
110. Tessem, M. B.; Swanson, M. G.; Keshari, K. R.; Albers, M. J.; Joun, D.; Tabatabai, Z. L.; Simko, J. P.; Shinohara, K.; Nelson, S. J.; Vigneron, D. B.; Gribbestad, I. S.; Kurhanewicz, J. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn. Reson. Med. 2008, 60 (3), 510-516.
111. Brizel, D. M.; Schroeder, T.; Scher, R. L.; Walenta, S.; Clough, R. W.; Dewhirst, M. W.; Mueller-Klieser, W. Elevated tumor lactate concentrations predict for an increased risk of metastases in headand-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51(2), 349-353.
112. Serkova, N. J.; Gamito, E. J.; Jones, R. H.; O'Donnell, C.; Brown, J. L.; Green, S.; Sullivan, H.; Hedlund, T.; Crawford, E. D. The metabolites citrate, myo-inositol, and spermine are potential ageindependent markers of prostate cancer in human expressed prostatic secretions. Prostate 2008, 68, 620-628.
113. Watanabe, N.; Okochi, E.; Mochizuki, M.; Sugimura, T.; Ushijima, T. The presence of single nucleotide instability in human breast cancer cell lines. Cancer Res. 2001, 61(21), 7739-7742.
114. 1H nuclear magnetic resonance spectroscopy characterisation of metabolic phenotypes in the medulloblastoma of the SMO transgenic mice. Br. J. Cancer 2010, 103(8), 1297-1304.
115. Keshari, K, R.; Sriram, R.; Van, Criekinge, M.; Wilson, D. M.; Wang, Z. J.; Vigneron, D. B.; Peehl, D. M.; Kurhanewicz, J. Metabolic reprogramming and validation of hyperpolarized 13 C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate 2013, 73(11), 1171-1181.
116. Zhou, X.; Mao, J.; Ai, J.; Deng, Y.; Roth, M. R.; Pound, C.; Henegar, J.; Welti, R.; Bigler, S. A. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PLoS One 2012, 7(11), e48889.
117. Chajès, V.; Joulin, V.; Clavel-Chapelon, F. The fatty acid desaturation index of blood lipids, as a biomarker of hepatic stearoyl-CoA desaturase expression, is a predictive factor of breast cancer risk. Curr. Opin. Lipidol. 2011, 22(1), 6-10.
118. Pyragius, C. E.; Fuller, M.; Ricciardelli, C.; Oehler, M. K. Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer. Int. J. Mol. Sci. 2013, 14(4), 7742-7756.
119. Sorongon-Legaspi, M. K.; Chua, M.; Sio, M. C.; Morales, M. Jr. Blood level omega-3 Fatty acids as risk determinant molecular biomarker for prostate cancer. Prostate Cancer 2013, 2013: 875615.
120. Weinstein, S. J.; Mackrain, K.; Stolzenberg-Solomon, R.; Selhub, J.; Virtamo, J.; Albanes, D. Serum creatinine and prostate cancer risk in a prospective study. Cancer Epidemiol. Biomarkers Prev. 2009, 18(10), 2643-2649.
121. Giskeødegård, G. F.; Bertilsson, H.; Selnæs, K. M.; Wright, A. J.; Bathen, T. F.; Viset, T.; Halgunset, J.; Angelsen, A.; Gribbestad, I. S.; Tessem, M. B. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLoS One 2013, 8(4), e62375.
122. López, E.; Cho, W. C. Proteomics and cancer research. In: Human Proteomic Bioinformatics; Wang Xiangdong, Ed.; Translational Bioinformatics, Springer Dordrecht Heidelberg New York, 2013; Vol. 3, pp. 75-101.
123. Jain, K. K. Applications of proteomics in oncology. Pharmaco-genomics 2000, 1, 385-393.
124. Wu, K.; Huang, R. S.; House, L.; Cho, W. C. Next-generation sequencing for lung cancer. Future Oncol. 2013, 9(9), 1323-1336.
125. Cho, W. C. Proteomics and translational medicine: molecular biomarkers for cancer diagnosis, prognosis and prediction of therapy outcome. Expert Rev. Proteomics 2011, 8(1), 1-4.
126. Xiao, Z.; Adam, B. L.; Cazares, L. H.; Clements, M. A.; Davis, J. W.; Schellhammer, P. F.; Dalmasso, E. A.; Wright, G. L. Jr. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 2001, 61, 6029-6033.
127. Hu, S.; Arellano, M.; Boontheung, P.; Wang, J.; Zhou, H.; Jiang, J.; Elashoff, D.; Wei, R.; Loo, J. A.; Wong, D. T. Salivary Proteomics for oral cancer biomarker discovery. Clin. Cancer Res. 2008, 14, 6246-6254.
128. Shreeve, R. L.; Banks, R. E.; Selby, P. J.; Vasudev, N. S. Proteomic study of conditioned media, cancer biomarker discovery. Int. J. Genomics Proteomics 2012, 3(1), 50-56.
129. Pan, S.; Chen, R.; Brand, R. E.; Hawley, S.; Tamura, Y.; Gafken, P. R.; Milless, B. P.; Goodlett, D. R.; Rush, J.; Brentnall, T. A. Multiplex targeted proteomic assay for biomarker detection in plasma, a pancreatic cancer biomarker case study. J. Proteome Res. 2012, 11(3), 1937-1948.
130. Leamon, C. P.; Lovejoy, C. D.; Nguyen, B. Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmgenomics Pers. Med. 2013, 6, 113-125.
131. Marimuthu, A.; Chavan, S.; Sathe, G.; Sahasrabuddhe, N. A.; Srikanth, S. M.; Renuse, S.; Ahmad, S.; Radhakrishnan, A.; Barbhuiya, M. A.; Kumar, R. V.; Harsha, H. C.; Sidransky, D.; Califano, J.; Pandey, A.; Chatterjee, A. Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochim. Biophys. Acta 2013, 1834(11), 2308-2316.
132. Makawita, S.; Smith, C.; Batruch, I.; Zheng, Y.; Rückert, F.; Grützmann, R.; Pilarsky, C.; Gallinger, S.; Diamandis, E. P. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics 2011, 10(10), M111. 008599.
133. Tabernero, M. D.; Lv, L. L.; Anderson, K. S. Autoantibody profiles as biomarkers of breast cancer. Cancer Biomark. 2010, 6(5-6), 247-256.
134. Wandall, H. H.; Blixt, O.;, Tarp, M. A.; Pedersen, J. W.; Bennett, E. P.; Mandel, U.; Ragupathi, G.; Livingston, P. O.; Hollingsworth, M. A.; Taylor-Papadimitriou, J.; Burchell, J.; Clausen, H. Cancer biomarkers defined by autoantibody signatures to aberrant oglycopeptide epitopes. Cancer Res. 2010, 70(4), 1306-1313.
135. Miller, J. C.; Zhou, H.; Kwekel, J.; Cavallo, R.; Burke, J.; Butler, E. B.; Teh, B. S.; Haab, B. B. Antibody microarray profiling of human prostate cancer sera, antibody screening and identification of potential biomarkers. Proteomics 2003, 3(1), 56-63.
136. Josephs, D.; Spicer, J.; O'Doherty, M. Molecular imaging in clinical trials. Target Oncol. 2009, 4(3), 151-168.
137. Gralow, J. R.; Biermann, J. S.; Farooki, A.; Fornier, M. N.; Gagel, R. F.; Kumar, R. N.; Shapiro, C. L.; Shields, A.; Smith, M. R.; Srinivas, S.; Van Poznak, C. H. NCCN task force report: Bone health in cancer care. J. Natl. Compr. Canc. Netw. 2009, 7(S3), S1-32; quiz S33-5.
138. Nanni, C.; Zamagni, E.; Farsad, M.; Castellucci, P.; Tosi, P.; Cangini, D.; Salizzoni, E.; Canini, R.; Cavo, M.; Fanti, S. Role of 18F-FDG PET/CT in the assessment of bone in newly diagnosed multiplemyeloma, preliminary results. Eur. J. Nucl. Med. Mol. Imaging 2006, 33(5), 525-531.
139. Farma, J. M.; Santillan, A. A.; Melis, M.; Walters, J.; Belinc, D.; Chen, D. T.; Eikman, E. A.; Malafa, M. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann. Surg. Oncol. 2008, 15(9), 2465-2471.
140. Antoch, G.; Stattaus, J.; Nemat, A. T.; Marnitz, S.; Beyer, T.; Kuehl, H.; Bockisch, A.; Debatin, J. F.; Freudenberg, L. S. Non-small cell lung cancer, dual-modality PET/CT in preoperative staging. Radiology 2003, 229(2), 526-533.
141. Griffeth, L. K. Use of PET/CT scanning in cancer patients, technical and practical considerations. Proc. (Bayl Univ Med Cent) 2005, 18(4), 321-330.
142. Wong, K. K.; Zarzhevsky, N.; Cahill, J. M.; Frey, K. A.; Avram, A. M. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR Am. J. Roentgenol. 2008, 191(6), 1785-1794.
143. Wong, K. H.; Tang, H. R.; Da Silva, A. J.; Wu, M. C.; Iwata, K.; Hasegawa, B. H. Improved quantitative imaging for In-111-ProstaScint using CT/SPECT and dual-energy reconstruction. J. Nucl. Med. 2000, 41, 18.
144. Chopra, S.; Verma, A.; Kundu, S.; Engineer, R.; Medhi, S.; Mahantshetty, U.; Gupta, S.; Shrivastava, S. K. Evaluation of diffusion-weighted imaging as a predictive marker for tumor response in patients undergoing chemoradiation for postoperative recurrences of cervical cancer. J. Cancer Res. Ther. 2012, 8(1), 68-73.
145. Aydn, H.; Kzlgöz, V.; Tatar, I. G.; Damar, C.; Ugan, A. R.; Paker, I.; Hekimoǧlu, B. Detection of prostate cancer with magnetic resonance imaging, optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings. journal of computer assisted tomography. J. Comput. Assist. Tomogr. 2012, 36(1), 30-45.
146. Jacobs, M. A.; Barker, P. B.; Argani, P.; Ouwerkerk, R.; Bhujwalla, Z. M.; Bluemke, D. A. Combined dynamic contrast enhanced breast MR and proton spectroscopic imaging, a feasibility study. J. Magn. Reson. Imaging 2005, 21 (1), 23-28.
147. Del Sole, A.; Falini, A.; Ravasi, L.; Ottobrini, L.; De Marchis, D.; Bombardieri, E.; Lucignani, G. Anatomical and biochemical investigation of primary brain tumours. Eur. J. Nucl. Med. 2001, 28(12), 1851-1872.
148. Preul, M. C.; Caramanos, Z.; Collins, D. L.; Villemure, J. G.; Leblanc, R.; Olivier, A.; Pokrupa, R.; Arnold, D. L. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat. Med. 1996, 2 (3), 323-325.
149. Gluch, L. Magnetic resonance in surgical oncology, II-literature review. ANZ J. Surg. 2005, 75(6), 464-470.
150. Mahon, M. M.; Williams, A. D.; Soutter, W. P.; Cox, I. J.; McIndoe, G. A.; Coutts, G. A.; Dina, R.; deSouza, N. M. 1H magnetic resonance spectroscopy of invasive cervical cancer, an in vivostudy with ex vivocorroboration. NMR Biomed. 2004, 17(1), 1-9.
151. Cho, S. G.; Lee, D. H.; Lee, K. Y.; Ji, H.; Lee, K. H.; Ros, P. R.; Suh, C. H. Differentiation of chronic focal pancreatitis from pancreatic carcinoma by in vivoproton magnetic resonance spectroscopy. J. Comput. Assist. Tomogr. 2005, 29(2), 163-169.
152. Shah, N.; Sattar, A.; Benanti, M.; Hollander, S.; Cheuck, L. Magnetic resonance spectroscopy as an imaging tool for cancer, a review of the literature. J. Am. Osteopath. Assoc. 2006, 106(1), 23-27.
153. Bergmann, A.; de Resende, J. M. D.; Santos-Filho, S. D.; Bello, M. A.; de Oliveira, J. F.; Palestro, C. J.; Bernardo-Filho, M. Lymphoscintigraphy in breast cancer, a short review about the impact on upper limb after surgical treatment. Braz. Arch. Biol. Technol. 2008, 51, 83-89.
154. Illidge, T.; Morschhauser, F. Radioimmunotherapy in follicular lymphoma. Best Pract. Res. Clin. Haematol. 2011, 24(2), 279-293.
155. El Ayed, M.; Bonnel, D.; Longuespée, R.; Castelier, C.; Franck, J.; Vergara, D.; Desmons, A.; Tasiemski, A.; Kenani, A.; Vinatier, D.; Day, R.; Fournier, I.; Salzet, M. MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying and validating biomarkers. Med. Sci. Monit. 2010, 16(8), BR233-45.
156. Pevsner, P. H.; Melamed, J.; Remsen, T.; Kogos, A.; Francois, F.; Kessler, P.; Stern, A.; Anand, S. Mass spectrometry MALDI imaging of colon cancer biomarkers, a new diagnostic paradigm. Biomark. Med. 2009, 3(1), 55-69.
157. Nair, M.; Jain, R.; Saxena, P.; Reality check: Cancer stem cell route to cancer. Curr. Biotech. 2013, 2(2), 89-105.
158. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344(11), 783-792.
159. Luporsi, E.; André, F.; Spyratos, F.; Martin, P. M.; Jacquemier, J.; Penault-Llorca, F.; Tubiana-Mathieu, N.; Sigal-Zafrani, B.; Arnould, L.; Gompel, A.; Egele, C.; Poulet, B.; Clough, K. B.; Crouet, H.; Fourquet, A.; Lefranc, J. P.; Mathelin, C.; Rouyer, N.; Serin, D.; Spielmann, M.; Haugh, M.; Chenard, M. P.; Brain, E.; de Cremoux, P.; Bellocq, J. P. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res. Treat 2012, 132(3), 895-915.
160. James C. R.; Quinn, J. E.; Mullan, P. B.; Johnston, P. G.; Harkin, D. P. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 2007, 12(2), 142-150.
161. Inwald, E. C.; Klinkhammer-Schalke, M.; Hofstädter, F.; Zeman, F.; Koller, M.; Gerstenhauer, M.; Ortmann, O. Ki-67 is a prognostic parameter in breast cancer patients: results of a large populationbased cohort of a cancer registry. Breast Cancer Res. Treat 2013, 139(2), 539-552.
162. Farazi, T. A.; Horlings, H. M.; Ten Hoeve, J. J.; Mihailovic, A.; Halfwerk, H.; Morozov, P.; Brown, M.; Hafner, M.; Reyal, F.; van Kouwenhove, M.; Kreike, B.; Sie, D.; Hovestadt, V.; Wessels, L. F.; van de Vijver, M. J.; Tuschl, T. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 2011, 71(13), 4443-4453.
163. Hafez, M. M.; Hassan, Z. K.; Zekri, A. R.; Gaber, A. A.; Al Rejaie, S. S.; Sayed-Ahmed, M. M.; AlShabanah, O. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pac. J. Cancer Prev. 2012, 13(2), 591-598.
164. Krell, J.; Frampton, A. E.; Jacob, J.; Castellano, L.; Stebbing, J. miRNAs in breast cancer: ready for real time? Pharmacogenomics 2012, 13(6), 709-719.
165. Stricker, T.; Catenacci, D. V.; Seiwert, T. Y. Molecular profiling of cancer-the future of personalized cancer medicine: A primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin. Oncol. 2011, 38, 173-185.
166. Vucic, E. A.; Thu, K. L.; Robison, K.; Rybaczyk, L. A.; Chari, R.; Alvarez, C. E.; Lam, W. L. Translating cancer 'omics' to improved outcomes. Genome Res. 2012, 22(2), 188-195.
167. Borgan, E.; Sitter, B.; Lingjærde, O. C.; Johnsen, H.; Lundgren, S.; Bathen, T. F.; Sørlie T.; Børresen-Dale, A. L.; Gribbestad, I. S. Merging transcriptomics and metabolomics--advances in breast cancer profiling. BMC Cancer 2010, 10, 628.
168. Jain, K. K. Personalized medicine for cancer, from drug development into clinical practice. Expert. Opin. Pharmacother. 2005, 6, 1463-1476.
169. Wong, H. R.; Weiss, S. L.; Giuliano, J. S. Jr.; Wainwright, M. S.; Cvijanovich, N. Z.; Thomas, N. J.; Allen, G. L.; Anas, N.; Bigham, M. T.; Hall, M.; Freishtat, R. J.; Sen, A.; Meyer, K.; Checchia, P. A.; Shanley, T. P.; Nowak, J.; Quasney, M.; Chopra, A.; Fitzgerald, J. C.; Gedeit, R.; Banschbach, S.; Beckman, E.; Lahni, P.; Hart, K.; Lindsell, C. J. Testing the prognostic accuracy of the updated pediatric sepsis biomarker risk model. PLoS One 2014, 9(1), e86242.